Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV vaccine formulation 4
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RSV vaccine formulation 4 is an mRNA vaccine developed by Sanofi. It is formulated with lipid nanoparticles (LNP) and utilizes the Respiratory Syncytial Virus (RSV) pre-F antigen to elicit an immune response. It is administered as an intramuscular injection.
- Other names
- RSV vaccine formulation 4 dose
02
Targets
RSV preF (Respiratory syncytial virus prefusion F glycoprotein)
Beyond the preview
Go deeper on RSV vaccine formulation 4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV vaccine formulation 4.